Generate Biomedicines starts Phase 3 SOLAIRIA trials of GB-0895 in severe uncontrolled asthma

Generate Biomedicines started Phase 3 SOLAIRIA trials of GB-0895 in severe uncontrolled asthma.

• Generate Biomedicines presented Phase 1 data for GB-0895, a long-acting anti-TSLP antibody being developed for asthma.
• The readout showed durable anti-inflammatory activity with a tolerability profile consistent with placebo, supporting dosing as infrequently as twice yearly.
• Biomarker effects appeared to plateau at the selected dose, reducing the case for higher dosing and supporting a simpler commercial regimen.
• Two global Phase 3 trials, SOLAIRIA-1 and SOLAIRIA-2, are underway in severe uncontrolled asthma to test clinical outcomes over 52 weeks.